** Ireland-based commercial stage biotechnology company Trinity Biotech's TRIB.O shares rise 8.7% to $0.73 premarket
** Co says it will strengthen focus on its Continuous Glucose Monitoring (CGM) technology
** Says that the successful execution of its comprehensive transformation plan is expected to drive near-term profitability improvements
** Co also appoints Barclays as its exclusive financial advisor to support strategic realignment
** Up to Wednesday's close, stock had fallen 22.7% so far this year
(Reporting by Anushka Chourasia)
((Anushka.Chourasia@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.